Dopamine D3 and D2 receptor mechanisms in the abuse-related behavioral effects of cocaine: Studies with preferential antagonists in squirrel monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 2, 2010, Pages 556-565

  Achat Mendes, Cindy ^a   Grundt, Peter ^b   Cao, Jianjing ^b   Platt, Donna M ^a   Newman, Amy Hauck ^b   Spealman, Roger D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [4 (4 CHLOROPHENYL) 4 HYDROXYPIPERIDIN 1 YL]METHYL 1H INDOLE; 3,4,4A,10B TETRAHYDRO 4 PROPYL 2H,5H [1]BENZOPYRANO[4,3 B][1,4]OXAZIN 9 OL; COCAINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; L 741626; N [4 (4 (2,3 DICHLOROPHENYL)PIPERAZIN 1 YL) TRANS BUT 2 ENYL] 4 PYRIDINE 2 YL BENZAMIDE HYDROCHLORODE; PG 01037; SUMANIROLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; COCAINE DEPENDENCE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG SELF ADMINISTRATION; NONHUMAN; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUANTITATIVE STUDY; SQUIRREL MONKEY;

ANIMALS; BEHAVIOR, ANIMAL; BENZAMIDES; BENZIMIDAZOLES; BENZOPYRANS; COCAINE-RELATED DISORDERS; DISCRIMINATION LEARNING; INDOLES; OXAZINES; PIPERIDINES; PYRIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SAIMIRI;

EID: 77954920607     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.167619     Document Type: Article

References (35)

1. Achat-Mendes C, Platt DM, Newman AH, and Spealman RD (2009) The dopamine D3 receptor partial agonist CJB 090 inhibits the discriminative stimulus but not the reinforcing or priming effects of cocaine in squirrel monkeys. Psychopharmacology (Berl) 206:73-84.
2. Acri JB, Carter SR, Alling K, Geter-Douglass B, Dijkstra D, Wikström H, Katz JL, and Witkin JM (1995) Assessment of cocaine-like discriminative stimulus effects of dopamine D3 receptor ligands. Eur J Pharmacol 281:R7-R9.
3. Baladi MG, Newman AH, and France CP (2010) Dopamine D3 receptors mediate the discriminative stimulus effects of quinpirole in free-feeding rats. J Pharmacol Exp Ther 332:308-315.
4. Beaulieu JM, Tirotta E, Sotnikova TD, Masri B, Salahpour A, Gainetdinov RR, Borrelli E, and Caron MG (2007) Regulation of Akt signaling by D2 and D3 dopamine receptors in vivo. J Neurosci 27:881-885.
5. Besson M, Belin D, McNamara R, Theobald DE, Castel A, Beckett VL, Crittenden BM, Newman AH, Everitt BJ, Robbins TW, et al. (2010) Dissociable control of impulsivity in rats by dopamine d2/3 receptors in the core and shell subregions of the nucleus accumbens. Neuropsychopharmacology 35:560-569.
6. Boeckler F and Gmeiner P (2007) Dopamine D3 receptor ligands: recent advances in the control of subtype selectivity and intrinsic activity. Biochim Biophys Acta 1768:871-887. (Pubitemid 46452549)
7. Costanza RM, Barber DJ, and Terry P (2001) Antagonism of the discriminative stimulus effects of cocaine at two training doses by dopamine D2-like receptor antagonists. Psychopharmacology (Berl) 158:146-153.
8. Dalley JW and Everitt BJ (2009) Dopamine receptors in the learning, memory and drug reward circuitry. Semin Cell Dev Biol 20:403-410.
9. Grundt P, Carlson EE, Cao J, Bennett CJ, McElveen E, Taylor M, Luedtke RR, and Newman AH (2005) Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. J Med Chem 48:839-848.
10. Grundt P, Husband SL, Luedtke RR, Taylor M, and Newman AH (2007a) Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR. Bioorg Med Chem Lett 17:745-779.
11. Grundt P, Prevatt KM, Cao J, Taylor M, Floresca CZ, Choi JK, Jenkins BG, Luedtke RR, and Newman AH (2007b) Heterocyclic analogues of N-(4-(4-(2,3- dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with functionalized linking chains as novel dopamine D3 receptor ligands: potential substance abuse therapeutic agents. J Med Chem 50:4135-4146.
12. 3 receptor antagonists as pharmacotherapeutics for addictions and related disorders. Ann NY Acad Sci 1187:4-34.
13. Heier RF, Dolak LA, Duncan JN, Hyslop DK, Lipton MF, Martin IJ, Mauragis MA, Piercey MF, Nichols NF, Schreur PJ, et al. (1997) Synthesis and biological activities of (R)-5,6-dihydro-N,N-dimethyl-4H-imidazo[4,5,1-ij]quinolin-5-amine and its metabolites. J Med Chem 40:639-646.
14. Higley AE, Spiller K, Grundt P, Newman AH, Kiefer SW, Xi ZZ, and Gardner EL (2010) PG01037, a novel dopamine D3 receptor antagonist, inhibits the effects of methamphetamine in rats. J Psychopharmacol doi:10.1177/0269881109358201.
15. Khroyan TV, Barrett-Larimore RL, Rowlett JK, and Spealman RD (2000) Dopamine D1- and D2-like receptor mechanisms in relapse to cocaine-seeking behavior: effects of selective antagonists and agonists. J Pharmacol Exp Ther 294:680-687.
16. Le Foll B, Francès H, Diaz J, Schwartz JC, and Sokoloff P (2002) Role of the dopamine D3 receptor in reactivity to cocaine-associated cues in mice. Eur J Neurosci 15:2016-2026.
17. Liu XY, Mao LM, Zhang GC, Papasian CJ, Fibuch EE, Lan HX, Zhou HF, Xu M, and Wang JQ (2009) Activity-dependent modulation of limbic dopamine D3 receptors by CaMKII. Neuron 61:425-438.
18. Martelle JL, Claytor R, Ross JT, Reboussin BA, Newman AH, and Nader MA (2007) Effects of two novel D3-selective compounds, NGB2904 [N-(4-(4-(2,3- dichlorophenyl) piperazin-1-yl)butyl)-9H-fluorene-2-carboxamide] and CJB090 [N-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butyl)-4-(pyridin-2-yl)benzamide], on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys. J Pharmacol Exp Ther 321:573-582.
19. Meador-Woodruff JH, Little KY, Damask SP, Mansour A, and Watson SJ (1993) Effects of cocaine on dopamine receptor gene expression: a study in the postmortem human brain. Biol Psychiatry 34:348-355.
20. Millan MJ, Iob L, Péglion JL, and Dekeyne A (2007) Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors. Psychopharmacology (Berl) 191:767-782.
21. Murray AM, Ryoo HL, Gurevich E, and Joyce JN (1994) Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA 91:11271-11275. (Pubitemid 24349668)
22. Platt DM, Carey G, and Spealman RD (2005) Intravenous self-administration techniques in monkeys. Curr Protoc Neurosci, Chapter 9, Unit 9.21.
23. Platt DM, Rodefer JS, Rowlett JK, and Spealman RD (2003) Suppression of cocaineand food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys. Psychopharmacology (Berl) 166:298-305.
24. Platt DM, Rowlett JK, and Spealman RD (2002) Behavioral effects of cocaine and dopaminergic strategies for preclinical medication development. Psychopharmacology (Berl) 163:265-282.
25. Pugsley TA, Davis MD, Akunne HC, MacKenzie RG, Shih YH, Damsma G, Wikstrom H, Whetzel SZ, Georgic LM, and Cooke LW (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther 275:1355-1366.
26. Rabiner EA, Slifstein M, Nobrega J, Plisson C, Huiban M, Raymond R, Diwan M, Wilson AA, McCormick P, Gentile G, et al. (2009) In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: studies in non-human primates and transgenic mice. Synapse 63:782-793.
27. Spealman RD (1996) Dopamine D3 receptor agonists partially reproduce the discriminative stimulus effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 278:1128-1137.
28. Staley JK and Mash DC (1996) Adaptive increase in D3 dopamine receptors in the brain reward circuits of human cocaine fatalities. J Neurosci 16:6100-6106.
29. Vanhauwe JF, Fraeyman N, Francken BJ, Luyten WH, and Leysen JE (1999) Comparison of the ligand binding and signaling properties of human dopamine D(2) and D(3) receptors in Chinese hamster ovary cells. J Pharmacol Exp Ther 290:908-916.
30. van Vliet LA, Rodenhuis N, Dijkstra D, Wikström H, Pugsley TA, Serpa KA, Meltzer LT, Heffner TG, Wise LD, Lajiness ME, et al. (2000) Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n- propyl-2H,5H [1]benzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907). J Med Chem 43:2871-2882.
31. Welter M, Vallone D, Samad TA, Meziane H, Usiello A, and Borrelli E (2007) Absence of dopamine D2 receptors unmasks an inhibitory control over the brain circuitries activated by cocaine. Proc Natl Acad Sci USA 104:6840-6845.
32. Xi ZX and Gardner EL (2008) Hypothesis-driven medication discovery for the treatment of psychostimulant addiction. Curr Drug Abuse Rev 1:303-327.
33. Xi ZX, Newman AH, Gilbert JG, Pak AC, Peng XQ, Ashby CR Jr, Gitajn L, and Gardner EL (2006) The novel dopamine D3 receptor antagonist NGB 2904 inhibits cocaine's rewarding effects and cocaine-induced reinstatement of drug-seeking behavior in rats. Neuropsychopharmacology 31:1393-1405.
34. Xu M, Koeltzow TE, Santiago GT, Moratalla R, Cooper DC, Hu XT, White NM, Graybiel AM, White FJ, and Tonegawa S (1997) Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron 19:837-848.
35. Zapata A and Shippenberg TS (2005) Lack of functional D2 receptors prevents the effects of the D3-preferring agonist (+)-PD 128907 on dialysate dopamine levels. Neuropharmacology 48:43-50. (Pubitemid 40022914)